# Amneal to Report Second Quarter 2026 Results on July 30, 2026
Canonical URL: https://biopharmsignal.com/news/AMRX/amneal-to-report-second-quarter-2026-results-on-july-30-2026-e7677e7f
Ticker: AMRX
Company: Amneal Pharmaceuticals
Source: Amneal Pharmaceuticals
Published: 2026-07-09 20:05 EST
Original Source URL: https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-to-Report-Second-Quarter-2026-Results-on-July-30-2026/default.aspx
## Summary

BRIDGEWATER, N.J., July 09, 2026 (GLOBE NEWSWIRE) - Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report second quarter 2026 financial results on Thursday, July 30, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be available through the Investor Relations section of the Company's website at investors.amneal.com . Individuals may register for the webcast by clicking here . To access the call by phone, dial 1 (833) 461-5787 (U.S.) or view a list of toll-free international numbers here . The access code for is 901153095. A replay of the webcast will be available shortly after the call. About Amneal Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Founded in 2002 by brothers and co-CEOs Chirag and

## Article Body
BRIDGEWATER, N.J., July 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report second quarter 2026 financial results on Thursday, July 30, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET.

The financial results and live webcast will be available through the Investor Relations section of the Company's website at investors.amneal.com . Individuals may register for the webcast by clicking here . To access the call by phone, dial 1 (833) 461-5787 (U.S.) or view a list of toll-free international numbers here . The access code for is 901153095. A replay of the webcast will be available shortly after the call.

About Amneal Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, Amneal was built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex, specialty and biosimilar medicines, delivering over 160 million prescriptions each year, primarily in the United States. Our Affordable Medicines segment spans retail, injectable, and biosimilar products. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For more information, visit and follow us on LinkedIn .

Investor Contact Anthony DiMeo VP, Investor Relations anthony.dimeo@amneal.com

Source: Amneal Pharmaceuticals LLC
## Recent Company News
- 2026-07-17 12:00 EST — [Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations](https://biopharmsignal.com/news/AMRX/amneal-expands-iohexol-injection-portfolio-with-u-s-fda-approval-of-additional-s-5f3ad56b) — Source: Amneal Pharmaceuticals
- 2026-07-09 20:05 EST — [Amneal to Report Second Quarter 2026 Results on July 30, 2026](https://biopharmsignal.com/news/AMRX/amneal-to-report-second-quarter-2026-results-on-july-30-2026-e7677e7f) — Source: Amneal Pharmaceuticals
- 2026-07-08 20:30 EST — [Amneal and Adalvo Announce FDA Acceptance for Review of Two U.S. ANDAs for Generic Tirzepatide Autoinjector](https://biopharmsignal.com/news/AMRX/amneal-and-adalvo-announce-fda-acceptance-for-review-of-two-u-s-andas-for-generi-0a6b37df) — Source: Amneal Pharmaceuticals
- 2026-07-01 12:30 EST — [Amneal’s New U.S. Sterile Manufacturing Facility Selected for FDA PreCheck Pilot Program](https://biopharmsignal.com/news/AMRX/amneal-s-new-u-s-sterile-manufacturing-facility-selected-for-fda-precheck-pilot--2719d102) — Source: Amneal Pharmaceuticals
- 2026-06-29 07:00 EST — [Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations](https://biopharmsignal.com/news/AMRX/zambon-and-amneal-announce-positive-chmp-opinion-for-hopledo-ipx203-for-adults-w-6b0e1405) — Source: Amneal Pharmaceuticals
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)